asset
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma
Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act
Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced
Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry
AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics
AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition
WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny
WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations
LEO Pharma’s Acquisition of Timber Pharmaceuticals’ Assets Faces Setback Due to Late-Stage Study Failure
LEO Pharma, Timber Pharmaceuticals, TMB-001, congenital ichthyosis, late-stage study failure, asset acquisition
Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment
Sanofi, dwarfism, mid-stage treatment, asset deprioritization, rare disease, achondroplasia
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options
TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales